Credo Health – a leader in technology for value-based care – recently announced it has successfully secured $5.25 million in series seed funding. FCA Venture Partners led the funding round with existing investors, including Hannah Grey VC, FirstMile Ventures, and SpringTime Ventures.
Credo Health is the only company that combines digital and manual medical record retrieval with AI-driven analysis and human expertise to ensure providers have the complete clinical picture of every patient.
This substantial funding round reinforces Credo Health’s mission to build the definitive platform for value-based care providers. Its core platform, PreDx, provides the complete clinical picture for every patient while supporting risk adjustment, quality, and health equity.
Credo Health’s forward momentum extends through strategic partnerships, including its recent collaboration with Vim – a middleware platform for healthcare that unlocks access to provider Electronic Health Record (EHR) workflow. And this partnership enhances EHR workflow integration with AI-powered medical retrieval and analysis, connecting providers and patients for improved healthcare outcomes.
Credo Health’s PreDx product has yielded impressive results, with organizations achieving much more accurate risk adjustment and quality scores while supporting higher quality care and patient satisfaction scores. These funds will further strengthen Credo’s technological infrastructure, expand its sales team, and continue driving innovation within the value-based care market.
KEY QUOTES:
“This investment is a testament to our commitment to fully support providers with the technology they need to succeed in value based care. It’s clear that value based care providers need a technology partner that not only empowers providers to deliver the highest quality patient care, but also one that ensures accurate, up to date risk adjustment and quality information that meets the latest regulatory guidelines.”
- Credo Founder and CEO Carm Huntress
“We’ve been looking deeply at technology across the value based care market and it was clear to us the team and technology were far superior to anything else we evaluated. We could not be more excited about our investment in Credo and the timing as we continue to see significant growth in value based care.”
- Tom Hearn, Partner at FCA Venture Partners and now Credo board member
